The FDA’s advisory committee has voted narrowly to ease restrictions on certain peptides, despite strong opposition from agency scientists. During the meeting, FDA scientists highlighted a lack of evidence and safety concerns regarding these compounds, which do not have universally accepted chemical formulas, complicating their evaluation. Popular in wellness circles and endorsed by figures like Robert F. Kennedy Jr. and Joe Rogan, these peptides are mostly found on the “grey market” and sold as “for research use only.”
The committee recommended adding peptides BPC-157, KPV, TB-500, and MOTS-c to a list of compounds that compounding pharmacies can make, though this does not equate to FDA approval. The final decision will be made through a proposed rule by the FDA.
Critics, including several committee members, expressed concerns about the lack of data supporting the peptides’ efficacy and safety, indicating that votes may have been influenced more by market demand than by scientific evidence. Proponents argued that allowing regulated access could help reduce grey market risks. A tension remained between promoting patient safety and the scientific basis for these treatments, with some members concerned about the ethical implications of their decisions.
Source link
